EGFP levels and toxicity in transgenic and virus injected animals.

Tonia S. Rex(Vanderbilt University Medical Center), Edward N. Pugh(Membrane Technology & Research (United States)), Elisabeth Bendo(California University of Pennsylvania), Jean Bennett(Penn Presbyterian Medical Center), Albert M. Maguire(Children's Hospital of Philadelphia), Enrico Maria Surace(Telethon Institute Of Genetics And Medicine), Thomas E. Hughes(Montana State University), Alberto Auricchio(Federico II University Hospital), J. Peet(University of Pennsylvania), Arkady Lyubarsky(Penn Presbyterian Medical Center)
Investigative Ophthalmology & Visual Science
May 1, 2004
Cited by 1

Related Papers

Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis
|New England Journal of Medicine|2008|2.1k
Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial
|The Lancet|2009|864
Gene Therapy for Leber's Congenital Amaurosis is Safe and Effective Through 1.5 Years After Vector Administration
|Molecular Therapy|2009|551
Mutation of a nuclear receptor gene, NR2E3, causes enhanced S cone syndrome, a disorder of retinal cell fate
|Nature Genetics|2000|506
Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
|The Lancet|2016|464